Bristol-Myers Squibb Sees Analyst Target Hike and Reports Positive Pediatric Heart Drug Trial
Scotiabank raised Bristol-Myers Squibb's price target to $60. The company announced positive Phase 3 results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.